Clinical update: new treatments for age-related macular degeneration

Lancet. 2007 Jul 21;370(9583):204-206. doi: 10.1016/S0140-6736(07)61104-0.

Authors

Tien Y Wong¹, Gerald Liew², Paul Mitchell²

Affiliations

¹ Centre for Eye Research, University of Melbourne, Melbourne 3002, Victoria, Australia; Singapore Eye Research Institute, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: twong@unimelb.edu.au.
² Centre for Vision Research, University of Sydney, NSW, Australia.

PMID: 17658379
DOI: 10.1016/S0140-6736(07)61104-0

No abstract available

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / pharmacokinetics
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Aptamers, Nucleotide / adverse effects
Aptamers, Nucleotide / pharmacokinetics
Aptamers, Nucleotide / therapeutic use*
Bevacizumab
Coronary Disease / chemically induced
Half-Life
Humans
Macular Degeneration / drug therapy*
Randomized Controlled Trials as Topic
Ranibizumab
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Aptamers, Nucleotide
Vascular Endothelial Growth Factor A
pegaptanib
Bevacizumab
Ranibizumab